Shenzhen Salubris Pharmaceuticals Co., Ltd.
AG·尊龙凯时
join us
CN
Home page
About Us
Profile
Affiliates/Subsidiaries
Development History
Quality Management
Contact Us
Legal Statement
Adverse Reaction Report
Science and Technology
R&D platform
R&D pipeline
Therapeutic Field
International Business
APIs
Finished Products
Medical device
Download product list
Contact
News Center
News & Trends
Public information
News & Trends
07
2024-04
JK07 for the treatment of chronic heart failure in adults was approved for Phase II clinical trial in China Abstract: A Phase II clinical trial in adults with chronic heart failure (RENEU-HF) was initiated
14
2023-12
Salubris' innovative drugs Allisartan and Enarodustat® were enrolled into 2023 National Reimbursement Drug List(NRDL)
10
2023-10
New overseas clinical progress of JK07 for the treatment of chronic heart failure (HFrEF)
08
2023-10
SAL0120 tablets for treatment of IgA nephropathy approved for clinical trial
10
2023-08
Vena cava filter system (SaExten®) approved by NMPA
09
2023-06
Enarodustat(恩那罗®) Approved by NMPA for Treatment of Renal Anemia (Abstract) NMPA approved Enarodustat(恩那罗®)
目前在第
1
页,
共有
9
页,
共有
51
条记录
第一页
上一页
1
2
3
4
5
下一页
最后一页
跳转到
页